Bryn Pharma
Bryn Pharma is a privately held, clinical-stage pharmaceutical company developing an intranasal epinephrine product for emergency treatment of anaphylaxis as a needle-free alternative to auto-injectors. The Raleigh, North Carolina–based LLC has raised approximately $125 million across six funding rounds from 2018 to 2023 but has not yet reported commercial revenue.
- Company typePrivate
- Founded2017
- HeadquartersBeverly Hills, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
Bryn Pharma firmographics
Firmographics- Name
- Bryn Pharma
- Legal name
- Bryn Pharma, LLC
- Website
- https://brynpharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bryn Pharma is a privately held, clinical-stage pharmaceutical company developing an intranasal epinephrine product for emergency treatment of anaphylaxis as a needle-free alternative to auto-injectors. The Raleigh, North Carolina–based LLC has raised approximately $125 million across six funding rounds from 2018 to 2023 but has not yet reported commercial revenue.
- Ownership category
- akta.pro rank
Bryn Pharma industry classification
Industry- Product category
- Allergy Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)
Keywords
Where Bryn Pharma is headquartered
LocationHeadquarters
- HQ city
- Beverly Hills
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Bryn Pharma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Securities offering: Company is raising capital through SEC exempt securities offerings under specific regulation exemptions. The offering has a total amount of $50 million with $43.5 million already sold, intended to last more than one year.
Bryn Pharma product offering
Product offeringCore offering
Bryn Pharma develops a needle-free, nasal-based epinephrine delivery product intended for the emergency treatment of severe allergic reactions, including anaphylaxis. The offering is designed to give patients and caregivers a non-injectable alternative to traditional epinephrine auto-injectors, addressing usability barriers such as needle phobia and administration difficulty during an emergency.
Differentiator
Problem solved
Functional benefit
Products and services
- Intranasal epinephrine product Needle-free, nasal spray–delivered epinephrine intended for the emergency treatment of severe allergic reactions, including anaphylaxis, in patients with a prescription and for administration by caregivers in out-of-hospital settings.
Companies that use Bryn Pharma
Customer profileIdeal customer profiles1 record
Bryn Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bryn Pharma partnerships and signals
Strategic signalScale indicators2 records
Bryn Pharma competitors and assessment
Company assessmentDirect peers
- ARS Pharmaceuticals: Developer of neffy, the first FDA-approved intranasal epinephrine spray for anaphylaxis. The closest direct competitor to Bryn's nasal epinephrine program, targeting the same indication, same route of administration, and same patient population.
- Kaleo (Auvi-Q): Markets Auvi-Q, a competing epinephrine auto-injector with voice-guided administration. Operates in the same anaphylaxis emergency-treatment market and competes directly with both traditional injectors and needle-free alternatives.
Broad incumbents
- Viatris: Global pharmaceutical company that owns the EpiPen brand, the dominant epinephrine auto-injector franchise. Any nasal epinephrine entrant must take share from Viatris's installed base of prescribers, patients, and pharmacy partners.
- Teva Pharmaceutical: Generic pharmaceutical manufacturer that supplies generic epinephrine auto-injectors. Competes on price in the same anaphylaxis market and represents the low-cost incumbent that any new entrant must position against.
- Amneal Pharmaceuticals: Generic and specialty pharmaceutical manufacturer with epinephrine injectable products. Comparable as a lower-priced epinephrine incumbent and as a peer in the broader specialty/sterile injectable pharma space.
- Bausch Health: Diversified specialty pharmaceutical company with allergy/emergency-adjacent portfolios. Relevant as a broad incumbent in the pharmaceutical categories Bryn would sell into.
- Hikma Pharmaceuticals: Specialty and generic pharmaceutical manufacturer with injectable epinephrine products. Comparable as a generic/specialty pharma peer competing in sterile injectable categories relevant to nasal and injectable drug delivery.
- Emergent BioSolutions: Specialty biopharmaceutical company focused on emergency preparedness and acute-care therapeutics. Comparable as a peer in the emergency-response and acute-care pharmaceutical space where anaphylaxis treatment sits.
Emerging players
- Adamis Pharmaceuticals (now USWM): Acquired by US WorldMeds; previously commercialized Symjepi, a pre-filled epinephrine syringe for anaphylaxis. Comparable as an alternative-format epinephrine competitor targeting the same patients via a different delivery device.
- Aquestive Therapeutics: Specialty pharma developing novel oral and sublingual drug delivery formats, including allergy and anaphylaxis-adjacent programs. Comparable as a company pursuing alternative drug-delivery routes to challenge injectable standards of care.
Market position
Customer concentration
Bryn Pharma social profiles
Digital presenceBryn Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bryn Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Bryn Pharma funding detail
Funding detailFunding overview
Funding rounds7 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bryn Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bryn Pharma
What does Bryn Pharma do?
Bryn Pharma develops a needle-free, nasal-based epinephrine delivery product intended for the emergency treatment of severe allergic reactions, including anaphylaxis. The offering is designed to give patients and caregivers a non-injectable alternative to traditional epinephrine auto-injectors, addressing usability barriers such as needle phobia and administration difficulty during an emergency.
Is Bryn Pharma a public or private company?
Bryn Pharma is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bryn Pharma founded?
Bryn Pharma was founded in 2017. It employs 1 to 10 people.
Where is Bryn Pharma based?
Bryn Pharma is headquartered in Beverly Hills, United States, in the North America region.
How does Bryn Pharma make money?
One revenue line is on record: securities offering.
Who are Bryn Pharma's main competitors?
Direct peers on record are ARS Pharmaceuticals and Kaleo (Auvi-Q). Broad incumbents are Viatris, Teva Pharmaceutical, Amneal Pharmaceuticals, Bausch Health, Hikma Pharmaceuticals and Emergent BioSolutions. Emerging players are Adamis Pharmaceuticals (now USWM) and Aquestive Therapeutics.
Does Bryn Pharma have an API?
No public API is recorded for Bryn Pharma.
What industry is Bryn Pharma in?
Bryn Pharma's product category is Allergy Therapeutics. Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices). Its NAICS code is 325412 and its SIC code is 2834.